Trial Profile

A Phase I/II Study of Bacteriophage Therapy to Evaluate Safety, Tolerability, and Efficacy of Targeted "Personalized" Bacteriophage Treatments in Patients With Bacterial Infection of the Urinary Tract

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bacteriophage therapeutics-BiomX (Primary) ; Bacteriophage therapeutics-BiomX (Primary)
Indications Bacterial infections; Urinary tract infections
Focus Therapeutic Use
Acronyms BEUTIFL
Sponsors Adaptive Phage Therapeutics

01 Mar 2023 Status changed from active, no longer recruiting to discontinued.
25 Jan 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Feb 2023.
25 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Nov 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com